Atea Pharmaceuticals, Inc. Operating Income
Atea Pharmaceuticals, Inc. (AVIR) reported Operating Income of -$35.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$35.10M.
- Atea Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$48.01M.
- Atea Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$54.93M.
- Atea Pharmaceuticals, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$45.57M.
- Atea Pharmaceuticals, Inc. operating income (loss) for fiscal 2025 was -$180.89M.
- Atea Pharmaceuticals, Inc. operating income (loss) for fiscal 2024 was -$192.95M.
- Atea Pharmaceuticals, Inc. operating income (loss) for fiscal 2023 was -$164.16M.
- Atea Pharmaceuticals, Inc. operating income (loss) for fiscal 2022 was -$130.65M, a 194.42% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$35.10M 10-Q · filed 2026-08-12 | -$83.11M 10-Q · filed 2026-08-12 | -$138.04M derived: sum of 3 quarters · filed 2026-08-12 | -$183.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$48.01M 10-Q · filed 2026-05-12 | -$102.94M derived: sum of 2 quarters · filed 2026-05-12 | -$148.51M derived: sum of 3 quarters · filed 2026-05-12 | -$189.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$54.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$100.50M derived: sum of 2 quarters · filed 2026-03-05 | -$141.85M derived: sum of 3 quarters · filed 2026-08-12 | -$180.89M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$45.57M 10-Q · filed 2025-11-12 | -$86.91M derived: sum of 2 quarters · filed 2026-08-12 | -$125.95M 10-Q · filed 2025-11-12 | -$164.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$41.34M 10-Q · filed 2026-08-12 | -$80.39M 10-Q · filed 2026-08-12 | -$119.41M derived: sum of 3 quarters · filed 2026-08-12 | -$156.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$39.04M 10-Q · filed 2026-05-12 | -$78.07M derived: sum of 2 quarters · filed 2026-05-12 | -$115.27M derived: sum of 3 quarters · filed 2026-05-12 | -$162.19M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$39.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$76.23M derived: sum of 2 quarters · filed 2026-03-05 | -$123.14M derived: sum of 3 quarters · filed 2026-03-05 | -$192.95M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$37.20M 10-Q · filed 2025-11-12 | -$84.12M derived: sum of 2 quarters · filed 2025-11-12 | -$153.92M 10-Q · filed 2025-11-12 | -$200.50M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$46.92M 10-Q · filed 2025-08-07 | -$116.72M 10-Q · filed 2025-08-07 | -$163.29M derived: sum of 3 quarters · filed 2025-08-07 | -$204.08M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$69.81M 10-Q · filed 2025-05-12 | -$116.38M derived: sum of 2 quarters · filed 2025-05-12 | -$157.16M derived: sum of 3 quarters · filed 2025-05-12 | -$192.40M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$46.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$87.36M derived: sum of 2 quarters · filed 2025-03-06 | -$122.59M derived: sum of 3 quarters · filed 2025-03-06 | -$164.16M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$40.78M 10-Q · filed 2024-11-07 | -$76.02M derived: sum of 2 quarters · filed 2024-11-07 | -$117.59M 10-Q · filed 2024-11-07 | -$157.49M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$35.23M 10-Q · filed 2024-08-07 | -$76.80M 10-Q · filed 2024-08-07 | -$116.70M derived: sum of 3 quarters · filed 2024-08-07 | -$132.98M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$41.57M 10-Q · filed 2024-05-14 | -$81.47M derived: sum of 2 quarters · filed 2024-05-14 | -$97.75M derived: sum of 3 quarters · filed 2024-05-14 | -$130.04M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$39.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$56.18M derived: sum of 2 quarters · filed 2024-02-28 | -$88.47M derived: sum of 3 quarters · filed 2024-02-28 | -$130.65M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$16.28M 10-Q · filed 2023-11-08 | -$48.58M derived: sum of 2 quarters · filed 2023-11-08 | -$90.75M 10-Q · filed 2023-11-08 | $30.43M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$32.30M 10-Q · filed 2023-08-08 | -$74.47M 10-Q · filed 2023-08-08 | $46.71M derived: sum of 3 quarters · filed 2023-08-08 | $24.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$42.17M 10-Q · filed 2023-05-08 | $79.01M derived: sum of 2 quarters · filed 2023-05-08 | $56.86M derived: sum of 3 quarters · filed 2023-05-08 | $65.55M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $121.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $99.03M derived: sum of 2 quarters · filed 2023-02-28 | $107.72M derived: sum of 3 quarters · filed 2023-02-28 | $138.38M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$22.15M 10-Q · filed 2022-11-07 | -$13.46M derived: sum of 2 quarters · filed 2022-11-07 | $17.20M 10-Q · filed 2022-11-07 | $37.84M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $8.69M 10-Q · filed 2022-08-08 | $39.34M 10-Q · filed 2022-08-08 | $59.99M derived: sum of 3 quarters · filed 2023-02-28 | $42.36M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $30.66M 10-Q · filed 2022-05-10 | $51.30M derived: sum of 2 quarters · filed 2023-02-28 | $33.67M derived: sum of 3 quarters · filed 2023-02-28 | $23.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $20.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.02M derived: sum of 2 quarters · filed 2023-02-28 | -$6.99M derived: sum of 3 quarters · filed 2023-02-28 | -$11.03M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$17.63M 10-Q · filed 2021-11-12 | -$27.63M derived: sum of 2 quarters · filed 2021-11-12 | -$31.68M 10-Q · filed 2021-11-12 | -$36.43M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$10.00M 10-Q · filed 2021-08-12 | -$14.05M 10-Q · filed 2021-08-12 | -$18.80M derived: sum of 3 quarters · filed 2022-02-28 | -$22.57M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$4.04M 10-Q · filed 2021-05-13 | -$8.79M derived: sum of 2 quarters · filed 2022-02-28 | -$12.56M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$8.52M derived: sum of 2 quarters · filed 2022-02-28 | -$14.61M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$3.77M 10-Q · filed 2020-12-10 | -$9.86M 10-Q · filed 2020-12-10 | ||
| 2018-12-31 | -$9.48M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |